

DAFTAR PUSTAKA

- Acan, D., Calan, M., Er, D., Arkan, T., Kocak, N., Bayraktar, F. and Kaynak, S. (2018). The prevalence and systemic risk factors of diabetic macular edema: A cross-sectional study from Turkey. *BMC Ophthalmol.* BMC Ophthalmology, 18(1), 1–8.
- Adelman, R. A., Zheng, Q. and Mayer, H. R. (2010). Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. *J. Ocul. Pharmacol. Ther.*, 26(1), 105–110.
- Agathokleous, E. and Calabrese, E. J. (2019). Hormesis: The dose response for the 21st century: The future has arrived. *Toxicology*, 425, 152249.
- Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., Nguyen, H. V., Aiello, L. M., Ferrara, N. and King, G. L. (1994). Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. *N. Engl. J. Med.*, 331(22), 1480–1487.
- Al-Latayfeh, M., Silva, P. S., Sun, J. K. and Aiello, L. P. (2012). Antiangiogenic therapy for ischemic retinopathies. *Cold Spring Harb. Perspect. Med.*, 2(6), 1–20.
- Alnagdy, A. A., Abouelkheir, H. Y., El-Khouly, S. E. and Tarshouby, S. M. (2018). Impact of topical nonsteroidal anti-inflammatory drugs in prevention of macular edema following cataract surgery in diabetic patients. *Int. J. Ophthalmol.*, 11(4), 616–622.
- Ang, W. J., Zunaina, E., Norfadzillah, A. J., Raja-Norliza, R. O., Julieana, M., Ab-Hamid, S. A. and Mahaneem, M. (2019). Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients. *PLoS One*, 14(8), 1–12.
- Arjamaa, O. and Nikinmaa, M. (2006). Oxygen-dependent diseases in the retina: Role of hypoxia-inducible factors. *Exp. Eye Res.*, 83(3), 473–483.
- Asghar, A., Rizwan, A., Obaid, N., Sughara, U. and Naeem, B. A. (2019). Intravitreal Bevacizumab(IVB): Safety of Multiple Doses Preparation from a Single Vial in Tertiary Care Centre. *Pakistan J. Ophthalmol.*, 35(4), 235–241.
- Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A. A. N. A., Rabena, M. D., Maia, M., Everen, S. V. A. N., Harm, P. D., Le, K. H. A. and Hanley, W. D. (2017). Systemic Pharmacokinetics and Pharmacodynamics of. *Retina*, 37, 1847–1858.
- Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S. and Singh, R. J. (2007). Pharmacokinetics of Intravitreal Bevacizumab (Avastin). *Ophthalmology*, 114(5), 855–859.
- Bakri, S. J., Pulido, J. S., McCannel, C. A., Hodge, D. O., Diehl, N. and Hillemeier, J. (2009). Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. *Eye*, 23(1), 181–185.
- Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P. and Ianchulev, T. (2009). Ranibizumab versus Verteporfin Photodynamic Therapy for

- Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. *Ophthalmology*, 116(1), 57-65.e5.
- Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S. and Tong, Y. (2019). Incidence of endophthalmitis after vitrectomy: A Systematic Review and Meta-analysis. *Retina*, 39(5), 844–852.
- Csaky, K. and Do, D. V. (2009). Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies. *Am. J. Ophthalmol.* Elsevier Inc., 148(5), 647–656.
- D’Amico, A. G., Maugeri, G., Bucolo, C., Saccone, S., Federico, C., Cavallaro, S. and D’Agata, V. (2017). Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats. *J. Mol. Neurosci.* Journal of Molecular Neuroscience, 61(2), 256–266.
- Das, A., McGuire, P. G. and Rangesamy, S. (2015). Diabetic macular edema: pathophysiology and novel therapeutic targets. *Ophthalmology*, 122(7), 1375–1394.
- Denisin, A. K., Karns, K. and Herr, A. E. (2012). Post-collection processing of Schirmer strip-collected human tear fluid impacts protein content. *Analyst*, 137(21), 5088–5096.
- Doherty, T. J. (2012). Intravitreal Ketorolac for Chronic Uveitis and Macular Edema. *Arch. Ophthalmol.*, 130(4), 456.
- Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B. and Lipsky, P. E. (1998). Cyclooxygenase in biology and disease. *FASEB J.*, 12(12), 1063–73.
- Faghihi, H., Yahyapour, H., Mahmoudzadeh, R. and Faghihi, S. (2017). Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. *Med. Hypothesis, Discov. Innov. Ophthalmol. J.*, 6(3), 67–75.
- Falavarjani, K. G. and Nguyen, Q. D. (2013). Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. *Eye.* Nature Publishing Group, 27(7), 787–794.
- Falkenstein, I. A., Cheng, L. and Freeman, W. R. (2007). Changes of intraocular pressure after intravitreal injection of Bevacizumab (Avastin). *Retina*, 27(8), 1044–1047.
- Ferrara, N., Hillan, K. J., Gerber, H. P. and Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat. Rev. Drug Discov.*, 3(5), 391–400.
- Hagan, S., Martin, E. and Enríquez-de-Salamanca, A. (2016). Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. *EPMA J.*, 7(1), 15.
- Haritoglou, C., Maier, M., Neubauer, A. S. and Augustin, A. J. (2020). Current concepts of pharmacotherapy of diabetic macular edema. *Expert Opin. Pharmacother.* Taylor & Francis, 21(4), 467–475.
- Hillier, R. J., Ojaimi, E., Wong, D. T., Mak, M. Y. K., Berger, A. R., Kohly, R. P., Kertes, P. J., Forooghian, F., Boyd, S. R., Eng, K., Altomare, F., Giavedoni, L. R., Nisenbaum, R. and Muni, R. H. (2018). Aqueous humor

- cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema. *JAMA Ophthalmol.*, 136(4), 382–388.
- Hollands, H., Wong, J., Bruen, R., Campbell, R. J., Sharma, S. and Gale, J. (2007). Short-term intraocular pressure changes after intravitreal injection of bevacizumab. *Can. J. Ophthalmol.*, 42(6), 807–811.
- International Diabetes Federation (2019). *IDF Diabetes Atlas*.
- Jalil, A., Fenerty, C. and Charles, S. (2007). Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. *Eye*, 21(12), 1541–1541.
- Kaštelan, S., Orešković, I., Bišćan, F., Kaštelan, H. and Gverović Antunica, A. (2020). Inflammatory and angiogenic biomarkers in diabetic retinopathy. *Biochem. medica*, 30(3), 385–399.
- Kasza, M., Balogh, Z., Biro, L., Ujhelyi, B., Damjanovich, J., Csutak, A., Várdai, J., Berta, A. and Nagy, V. (2015). Vascular endothelial growth factor levels in tears of patients with retinal vein occlusion. *Graefes Arch. Clin. Exp. Ophthalmol.*, 253(9), 1581–1586.
- Kiddee, W., Trope, G. E., Sheng, L., Beltran-Agullo, L., Smith, M., Strungaru, M. H., Baath, J. and Buys, Y. M. (2013). Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review. *Surv. Ophthalmol.*, 58(4), 291–310.
- Kim, S. J., Adams, N. A., Toma, H. S., Belair, M. and Jabs, D. A. (2008). Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. *Retin. J. Retin. Vit. Dis.*, 595–605.
- Kim, S. J., Flach, A. J. and Jampol, L. M. (2010). Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. *Surv. Ophthalmol.* Elsevier Inc, 55(2), 108–133.
- Komarowska, I., Heilweil, G., Rosenfeld, P. J., Perlman, I. and Loewenstein, A. (2009). Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. *Retina*, 29(1), 98–105.
- Kotliar, K., Maier, M., Bauer, S., Feucht, N., Lohmann, C. and Lanzl, I. (2007). Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. *Acta Ophthalmol. Scand.*, 85(7), 777–781.
- Lee, J. W., Park, H., Choi, J. H., Lee, H. J., Moon, S. W., Kang, J. H. and Kim, Y. G. (2016). Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. *BMC Ophthalmol.*, 16(1), 69.
- Lee, R., Wong, T. Y. and Sabanayagam, C. (2015). Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vision*, 2(1), 1–25.
- Lee, T. H., Choi, W., Ji, Y. S. and Yoon, K. C. (2016). Comparison of ketorolac 0.45% versus diclofenac 0.1% for macular thickness and volume after uncomplicated cataract surgery. *Acta Ophthalmol.*, 94(3), e177–e182.
- Ma, Y., Zhang, Y., Zhao, T. and Jiang, Y. (2012). Vascular Endothelial Growth Factor in Plasma and Vitreous Fluid of Patients with Proliferative Diabetic Retinopathy Patients after Intravitreal Injection of Bevacizumab. *Am. J. Ophthalmol.*, 153(2), 307–313.e2.

- Magone, T. and Strauss, E. C. (2004). VEGF Levels In The Tears Of Soft Contact Lens Wearers. *Invest. Ophthalmol. Vis. Sci.*, 45(13), 1560.
- Maldonado, R. M., Vianna, R. N. G., Cardoso, G. P., De Magalhães, A. V. and Burnier, M. N. (2011). Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. *Curr. Eye Res.*, 36(8), 768–773.
- Mansoori, T., Agraharam, S. G., Manwani, S. and Balakrishna, N. (2021). Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study. *J. Curr. Ophthalmol.*, 33(1), 6–11.
- Meleth, A. D., Agrón, E., Chan, C. C., Reed, G. F., Arora, K., Byrnes, G., Csaky, K. G., Ferris, F. L. and Chew, E. Y. (2005). Serum inflammatory markers in diabetic retinopathy. *Investig. Ophthalmol. Vis. Sci.*, 46(11), 4295–4301.
- Melosky, B., Reardon, D. A., Nixon, A. B., Subramanian, J., Bair, A. H. and Jacobs, I. (2018). Bevacizumab biosimilars: Scientific justification for extrapolation of indications. *Futur. Oncol.*, 14(24), 2507–2520.
- Miyamoto, K., Khosrof, S., Bursell, S. E., Rohan, R., Murata, T., Clermont, A. C., Aiello, L. P., Ogura, Y. and Adamis, A. P. (1999). Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. *Proc. Natl. Acad. Sci. U. S. A.*, 96(19), 10836–10841.
- Mordenti, J., Cuthbertson, R. A., Ferrara, N., Thomsen, K., Berleau, L., Licko, V., Allen, P. C., Valverde, C. R., Meng, Y. G., Fei, D. T. W., Fourre, K. M. and Ryan, A. M. (1999). Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration. *Toxicol. Pathol.*, 27(5), 536–544.
- Pal, D. N., Subramanian, D. T., John Bosco, D. A. and Chawda, D. V. (2019). Comparative Study Of The Effect Of Topical Corticosteroid With Non-Steroidal Anti Inflammatory Agents On Post-Operative Inflammation And Corneal Astigmatism After Cataract Surgery. *J. Curr. Med. Res. Opin.*, 2(02), 95–99.
- Park, H. Y., Yi, K. and Kim, H. K. (2005). Intraocular Pressure Elevation after Intravitreal Triamcinolone Acetonide Injection. *Korean J. Ophthalmol.*, 19(2), 122.
- Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W. and Hartnett, M. E. (2008). Vascular endothelial growth factor in eye disease. *Prog. Retin. Eye Res.*, 27(4), 331–371.
- Pflugfelder, S. (2011). Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. *Am J Ophthalmol.*, 152(6), 900–909.
- Rabie, N. and Elgouhary, S. (2018). Association between aqueous IL-6 , TNF- A and VEGF with diabetic macular edema. *Arab J. Lab. Med.*, 43(September 2018), 907–914.
- Ranieri, G., Patruno, R., Ruggieri, E., Montemurro, S., Valerio, P. and Ribatti, D. (2006). Vascular Endothelial Growth Factor (VEGF) as a Target of

- Bevacizumab in Cancer: From the Biology to the Clinic. *Curr. Med. Chem.*, 13(16), 1845–1857.
- Rentka, A., Hársfalvi, J., Berta, A., Köröskényi, K., Szekanecz, Z., Szücs, G., Szodoray, P. and Kemény-Beke, Á. (2015). Vascular Endothelial Growth Factor in Tear Samples of Patients with Systemic Sclerosis. *Mediators Inflamm.*, 2015, 1–4.
- Rentka, A., Koroskenyi, K., Harsfalvi, J., Szekanecz, Z., Szucs, G., Szodoray, P. and Kemeny-Beke, A. (2017). Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis. *Ann. Clin. Biochem.*, 54(5), 521–529.
- Ricciotti, E. and FitzGerald, G. A. (2011). Prostaglandins and Inflammation. *Arterioscler. Thromb. Vasc. Biol.*, 31(5), 986–1000.
- Rifkin, L. and Schaal, S. (2012). Factors affecting patients' pain intensity during in office intravitreal injection procedure. *Retina*, 32(4), 696–700.
- Romero-Aroca, P., Pareja-Rios, A., Baget-Bernaldiz, M., Lopez-Galvez, M. and Navarro-Gil, R. (2016). Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. *J. Diabetes Res.*, 2016, no pagination.
- Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y. and Kim, R. Y. (2006). Ranibizumab for Neovascular Age-Related Macular Degeneration. *N. Engl. J. Med.*, 355(14), 1419–1431.
- Rossi, S., Mantelli, F., Lambiase, A. and Aloe, L. (2012). Bevacizumab eye drop treatment stimulates tear secretion in rats through changes in VEGF and NGF lacrimal gland levels. *Arch Ital Biol*, 150(1), 15–21.
- Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R., Dell'Omo, R. and Semeraro, F. (2013). Topical nonsteroidal anti-inflammatory drugs for macular edema. *Mediators Inflamm.*, 2013.
- Salinger, C. L., Gaynes, B. I. and Rajpal, R. K. (2019). Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain. *Am. J. Manag. Care*, 25(12 Suppl), S215–S226.
- Samoilov, A. N., Mustafin, I. G. and Korobitsyn, A. N. (2012). Tear fluid vascular endothelial growth factor level as a marker of effectiveness of proliferative diabetic retinopathy combined treatment. *Kazan Med. J.*, 93(6), 965–969.
- Sampat, K. M. and Garg, S. J. (2010). Complications of intravitreal injections. *Curr. Opin. Ophthalmol.*, 21(3), 178–183.
- Sastroasmoro, S. and Ismael, S. (2011). *Dasar-dasar Metodologi Penelitian Klinis*. 4th edn. Jakarta: Sagung Seto.
- Seok, S., Park, D., Kim, Y., Moon, C., Jung, Y., Baik, E., Moon, C. and Lee, S. (2006). COX-2 is associated with cadmium-induced ICAM-1 expression in cerebrovascular endothelial cells. *Toxicol. Lett.*, 165(3), 212–220.
- Shah, A. P., Sisk, R. A. and Foster, R. E. (2019). Complications of Serial Anterior Chamber Paracentesis for Increased Intraocular Pressure After Intravitreal Injections. *Retin. Cases Brief Rep.*, Publish Ah, 1–5.
- Sheikhrezaee, M., Alizadeh, M. R. and Abediankenari, S. (2020). The tear VEGF and IGFBP3 in healthy and diabetic retinopathy. *Int. J. Diabetes Dev. Ctries*. International Journal of Diabetes in Developing Countries, 40(1), 93–98.

- Singer, M. A., Kermany, D. S., Waters, J., Jansen, M. E. and Tyler, L. (2016). Diabetic macular edema: It is more than just VEGF. *F1000Research*, 5(May), 3–8.
- Singerman, L. J., Masonson, H., Patel, M., Adamis, A. P., Buggage, R., Cunningham, E., Goldbaum, M., Katz, B. and Guyer, D. (2008). Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. *Br. J. Ophthalmol.*, 92(12), 1606–1611.
- Takahashi, H., Nomura, Y., Nishida, J., Fujino, Y., Yanagi, Y. and Kawashima, H. (2016). Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs. *Investig. Ophthalmology Vis. Sci.*, 57(2), 462.
- Tolentino, M. (2011). Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. *Surv. Ophthalmol.* Elsevier Inc, 56(2), 95–113.
- Tsai, T., Kuehn, S., Tsiampalis, N., Vu, M. K., Kakkassery, V., Stute, G., Dick, H. B. and Joachim, S. C. (2018). Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. *PLoS One*, 13(3), 1–13.
- Tsilimbaris, M. K., Tsika, C. and Kymionis, G. D. (2016). Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery. *Ther. Clin. Risk Manag.*, 12, 177–182.
- Udaondo, P., Hernández, C., Briansó-Llort, L., García-Delpech, S., Simó-Servat, O. and Simó, R. (2019). Usefulness of Liquid Biopsy Biomarkers from Aqueous Humor in Predicting Anti-VEGF Response in Diabetic Macular Edema: Results of a Pilot Study. *J. Clin. Med.*, 8(11), 1841.
- Urias, E. A., Urias, G. A., Monickaraj, F., McGuire, P. and Das, A. (2017). Novel therapeutic targets in diabetic macular edema: Beyond VEGF. *Vision Res.* Elsevier, 139(March), 221–227.
- Vermes, I., Steinmetz, E. T., Zeyen, L. J. J. M. and van der Veen, E. A. (1987). Rheological properties of white blood cells are changed in diabetic patients with microvascular complications. *Diabetologia*, 30(6), 434–436.
- Vesaluoma, M., Teppo, A.-M., Grönhagen-Riska, C. and Tervo, T. (1997). Release of TGF- β 1 and VEGF in tears following photorefractive keratectomy. *Curr. Eye Res.*, 16(1), 19–25.
- Wafapoor, H. and McCluskey, J. (2006). Intravitreal Ketorolac as a Treatment of Diabetic and Non-Diabetic Macular Edema. *Invest. Ophthalmol. Vis. Sci.*, 47(13), 4252–4252.
- Wang, Juan-Juan; Zhu, Meili; Le, Y.-Z. (2015). Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy. *World J. Diabetes*, 6(5), 726.
- Wang, J.-Y., Kwon, J.-S., Hsu, S.-M. and Chuang, H.-S. (2020). Sensitive tear screening of diabetic retinopathy with dual biomarkers enabled using a rapid electrokinetic patterning platform. *Lab Chip*, 20(2), 356–362.
- Wang, X., Wang, G. and Wang, Y. (2009). Intravitreal Vascular Endothelial

- Growth Factor and Hypoxia-Inducible Factor 1a in Patients With Proliferative Diabetic Retinopathy. *Am. J. Ophthalmol.* Elsevier Inc., 148(6), 883–889.
- Waterbury, L. D., Silliman, D. and Jolas, T. (2006). Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. *Curr. Med. Res. Opin.*, 22(6), 1133–1140.
- Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Aiello, L. P., Antoszyk, A. N., Arnold-Bush, B., Baker, C. W., Bressler, N. M., Browning, D. J., Elman, M. J., Ferris, F. L., Friedman, S. M., Melia, M., Pieramici, J., Sun, J. K. and Beck, R. W. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N. Engl. J. Med.*, 372(13), 1193–1203.
- Williams, C. S., Mann, M. and DuBois, R. N. (1999). The role of cyclooxygenases in inflammation, cancer, and development. *Oncogene*, 18(55), 7908–7916.
- Yannuzzi, N. A., Patel, S. N., Bhavsar, K. V., Sugiguchi, F. and Freund, K. B. (2014). Predictors of Sustained Intraocular Pressure Elevation in Eyes Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. *Am. J. Ophthalmol.*, 158(2), 319–327.e2.
- Yenihayat, F., Özkan, B., Kasap, M., Karabaş, V. L., Güzel, N., Akpınar, G. and Pirhan, D. (2019). Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. *Int. Ophthalmol.*, 39(4), 821–828.
- Zhang, Q., Fang, W., Ma, L., Wang, Z.-D., Yang, Y.-M. and Lu, Y.-Q. (2018). VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes. *Medicine (Baltimore)*, 97(15), e0415.
- Zhang, R., Xu, Y., Fu, H., Wang, J., Jin, L. and Li, S. (2009). Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells. *Br. J. Pharmacol.*, 158(3), 819–829.
- Zur, D., Igllicki, M. and Loewenstein, A. (2019). The Role of Steroids in the Management of Diabetic Macular Edema. *Ophthalmic Res.*, 62(4), 231–236.